Prelude Therapeutics (PRLD) EPS (Diluted) Growth (1y) (2022 - 2026)
Powered by 
Analysis
Prelude Therapeutics (PRLD) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -11.18% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 96.41% |
| 10 | Prelude Therapeutics | 540.15 Mn | 259.53 Mn | - | 62.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.92% |
| Mar 31, 2026 | 62.28% |
| Dec 31, 2025 | 49.49% |
| Sep 30, 2025 | 40.82% |
| Jun 30, 2025 | 13.64% |
| Mar 31, 2025 | -0.43% |
| Dec 31, 2024 | 27.94% |
| Sep 30, 2024 | 8.18% |
| Jun 30, 2024 | 14.85% |
| Mar 31, 2024 | 25.65% |
| Dec 31, 2023 | 12.12% |
| Sep 30, 2023 | 22.98% |
| Jun 30, 2023 | 7.56% |
| Mar 31, 2023 | 5.22% |
| Dec 31, 2022 | 1.69% |
| Sep 30, 2022 | 3.72% |
| Jun 30, 2022 | -2.79% |